A detailed history of Stonnington Group, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Stonnington Group, LLC holds 10,025 shares of EXAS stock, worth $576,237. This represents 0.18% of its overall portfolio holdings.

Number of Shares
10,025
Previous 12,750 21.37%
Holding current value
$576,237
Previous $631,000 7.61%
% of portfolio
0.18%
Previous 0.18%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023

SELL
$47.19 - $70.77 $128,592 - $192,848
-2,725 Reduced 21.37%
10,025 $679,000
Q4 2022

Jan 11, 2023

BUY
$30.35 - $53.15 $386,962 - $677,662
12,750 New
12,750 $0
Q1 2022

Apr 12, 2022

SELL
$57.56 - $82.54 $314,277 - $450,668
-5,460 Closed
0 $0
Q4 2021

Jan 12, 2022

BUY
$72.5 - $100.68 $395,850 - $549,712
5,460 New
5,460 $433,000
Q3 2021

Oct 12, 2021

SELL
$90.24 - $124.05 $156,115 - $214,606
-1,730 Closed
0 $0
Q2 2021

Jul 09, 2021

BUY
$93.66 - $139.27 $162,031 - $240,937
1,730 New
1,730 $202,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Stonnington Group, LLC Portfolio

Follow Stonnington Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonnington Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonnington Group, LLC with notifications on news.